Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook

• Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales
• Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing
• 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year
• Chief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership

Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results1 and provided a first outlook for 2026.

2025 full-year revenue and cash results (unaudited):

• Total revenues of €174.7 million in 2025 compared to €169.6 million in 2024 including recognition of variable consideration relating to the research collaboration and licensing agreement for the Lyme disease program
• Product sales of €157.9 million compared to €163.3 million in 2024, as third-party sales decreased by 42.3% to €19.2 million (€33.2 million in 2024), as expected
• Product sales increased by 9% at constant exchange rate (CER)2) and excluding third-party sales
• Cash and cash equivalents of €109.7 million as of December 31, 2025, compared to €168.3 million as of December 31, 2024

2026 Outlook and Financial Guidance:

• First Phase 3 data readout for Lyme disease vaccine candidate anticipated in the first half of 2026, with regulatory submissions expected to follow as planned by Pfizer, subject to positive results If successful, VLA15 will be the fourth vaccine developed by Valneva and its successful commercialization by Pfizer would enable Valneva to further expand and accelerate a pipeline of innovative vaccines in line with its strategic vision
• First Phase 2 data for tetravalent shigella vaccine candidate S4V2 A decision on subsequent development steps is anticipated in the second half of 2026
• Progress in enhancing the R&D pipeline with differentiated vaccine candidates addressing areas of high unmet medical need
• Total revenues for 2026 are expected in the range of €155-170 million, including product sales between €145-160 million Lower product sales guidance in 2026 compared to 2025 reflects continued growth of established commercial brands, offset by the wind-down of third-party sales as previously guided.
• Disciplined cash management to continue with operating cash burn expected to decline further in 2026 while sustaining strategic R&D investments

Peter Bühler, Valneva’s Chief Financial Officer, commented, “2025 challenged our resilience while reaffirming the strength of our team’s disciplined execution. We remained committed to growing our commercial brands and made strong progress across our key R&D programs, despite headwinds around IXCHIQ® and the broader geopolitical pressures. As we enter 2026, we look forward to the potentially transformative Phase 3 data readout for our Lyme disease vaccine candidate, while remaining focused on prudent capital allocation, to support shaping and growing our business in line with our strategic vision.”

Valneva also announced today that its Board of Directors has renewed Thomas Lingelbach’s mandate as Chief Executive Officer for a further three-year term and confirmed his continued role as a Board member, subject to approval at the Company’s 2026 Annual General Meeting.

Anne-Marie Graffin, Chairperson of Valneva’s Board of Directors, commented, “As a co-founder of the Company, Thomas has been a driving force behind our growth, culture, and sustained success over the past 13 years. The Board firmly believes that his continued leadership is critical as we enter the next era of the Company’s development, and we have full confidence in his ability to drive the Company’s future and deliver value for all our stakeholders.”

Non-IFRS Financial Measures - Product sales (excluding third-party sales) at constant exchange rates:

References to changes in net sales at constant exchange rates (CER) indicate that the impact of currency fluctuations has been removed. This is done by recalculating net sales for the period in question using the exchange rates applied in the prior period.

€ in million

Twelve months ended December 31

(unaudited results, consolidated per IFRS)

2025

2024

Year-over-year growth %

Product sales

157.9

163.3

• 3.3%

Third-party product sales

19.2

33.2

• 42.3%

Product sales excluding third-party sales

138.7

130.1

• 6.7%

Effect of exchange rates (excluding third-party sales)

3.1

Product sales (excluding third-party sales) at constant exchange rates (CER)

141.8

• 9.0%

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 [email protected]

Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 [email protected]